Immune Design (IMDZ) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. ANT
6. JBLU
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Immune Design (IMDZ) Tops Q3 EPS by 2c

Immune Design Reports Third Quarter 2015 Financial Results

November 12, 2015 4:00 PM EST

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the third quarter ended September 30, 2015, which includes advancement of its immuno-oncology programs and a cash position of $120.5 million.

Corporate Update and Recent Highlights

Yesterday, Immune Design announced the dosing of the first patient in the randomized Phase 2 trial of CMB305, the company's "prime boost" immuno-oncology product candidate, combined with Genentech's investigational cancer immunotherapy, atezolizumab (MPDL3280A; anti-PD-L1)... More